Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lepore, M.
Right arrow Articles by Bolli, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lepore, M.
Right arrow Articles by Bolli, G. B.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 49, Issue 12 2142-2148, Copyright © 2000 by American Diabetes Association

ARTICLES

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

M Lepore, S Pampanelli, C Fanelli, F Porcellati, L Bartocci, A Di Vincenzo, C Cordoni, E Costa, P Brunetti and GB Bolli
Department of Internal Medicine, University of Perugia, Italy.

To compare the pharmacokinetics/dynamics of the long-acting insulin analog glargine with NPH, ultralente, and continuous subcutaneous (SC) infusion of insulin lispro (continuous subcutaneous insulin infusion [CSII]), 20 C-peptide-negative type 1 diabetic patients were studied on four occasions during an isoglycemic 24-h clamp. Patients received SC injection of either 0.3 U/kg glargine or NPH insulin (random sequence, crossover design). On two subsequent occasions, they received either an SC injection of ultralente (0.3 U/kg) or CSII (0.3 U x kg(-1) x 24 h(-1)) (random sequence, crossover design). After SC insulin injection or CSII, intravenous (IV) insulin was tapered, and glucose was infused to clamp plasma glucose at 130 mg/dl for 24 h. Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE). End of action (defined as an increase in plasma glucose >150 mg/dl) occurred later with glargine (22 +/- 4 h) than with NPH (14 +/- 3 h) (P < 0.05) but was similar with ultralente (20 +/- 6 h). NPH and ultralente exhibited a peak concentration and action (at 4.5 +/- 0.5 and 10.1 +/- 1 h, respectively) followed by waning, whereas glargine had no peak but had a flat concentration/action profile mimicking CSII. Interindividual variability (calculated as differences in SD of plasma insulin concentrations and glucose infusion rates in different treatments) was lower with glargine than with NPH and ultralente (P < 0.05) but was similar with glargine and CSII (NS). In conclusion, NPH and ultralente are both peak insulins. Duration of action of ultralente is greater, but intersubject variability is also greater than that of NPH. Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
F. Porcellati, P. Rossetti, N. R. Busciantella, S. Marzotti, P. Lucidi, S. Luzio, D. R. Owens, G. B. Bolli, and C. G. Fanelli
Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study
Diabetes Care, October 1, 2007; 30(10): 2447 - 2452.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
E. Hassan
Hyperglycemia management in the hospital setting
Am. J. Health Syst. Pharm., May 15, 2007; 64(10_Supplement_6): S9 - S14.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Porcellati, P. Rossetti, N. B. Ricci, S. Pampanelli, E. Torlone, S. H. Campos, A. M. Andreoli, G. B. Bolli, and C. G. Fanelli
Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes
Diabetes Care, May 1, 2007; 30(5): 1261 - 1263.
[Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
A. L. Trujillo
Insulin Analogs and Pregnancy
Diabetes Spectr, April 1, 2007; 20(2): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
V. Cherubini, A. Iannilli, D. Iafusco, F. Cardella, M. S. Giamprini, C. Fanelli, and G. V. Coppa
Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes
Diabetes Care, October 1, 2006; 29(10): 2311 - 2312.
[Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
F. M Regan and D. B Dunger
Use of new insulins in children
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. S. Schade and V. Valentine
Counterpoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? No.
Diabetes Care, June 1, 2006; 29(6): 1453 - 1455.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. N. Davis and S. M. Renda
Treating to Target in Type 2 Diabetes: A Case Presentation.
The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. D. Wittlin
Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy
The Diabetes Educator, January 1, 2006; 32(1): 39S - 46S.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
F. J. Ampudia-Blasco, J. Girbes, and R. Carmena
A Case of Lipoatrophy With Insulin Glargine: Long-acting insulin analogs are not exempt from this complication
Diabetes Care, December 1, 2005; 28(12): 2983 - 2983.
[Full Text] [PDF]

Home page
 PediatricsHome page
T. S. Hannon, G. Rao, and S. A. Arslanian
Childhood Obesity and Type 2 Diabetes Mellitus
Pediatrics, August 1, 2005; 116(2): 473 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
W. H. Herman, L. L. Ilag, S. L. Johnson, C. L. Martin, J. Sinding, A. Al Harthi, C. D. Plunkett, F. B. LaPorte, R. Burke, M. B. Brown, et al.
A Clinical Trial of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Older Adults With Type 2 Diabetes
Diabetes Care, July 1, 2005; 28(7): 1568 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
S. A. Weinzimer, E. A. Doyle, and W. V. Tamborlane Jr
Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Clinical Pediatrics, June 1, 2005; 44(5): 393 - 403.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, R. Gomis, and for the AT.LANTUS Study Group
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine
Diabetes Care, June 1, 2005; 28(6): 1282 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Plank, M. Bodenlenz, F. Sinner, C. Magnes, E. Gorzer, W. Regittnig, L. A. Endahl, E. Draeger, M. Zdravkovic, and T. R. Pieber
A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
Diabetes Care, May 1, 2005; 28(5): 1107 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. Weyer, M. S. Fineman, S. Strobel, L. Shen, J. Data, O. G. Kolterman, and M. F. Sylvestri
Properties of pramlintide and insulin upon mixing
Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 816 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Rosenstock, G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin, and A. Salzman
Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes
Diabetes Care, April 1, 2005; 28(4): 950 - 955.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. Stoneking
Initiating basal insulin therapy in patients with type 2 diabetes mellitus
Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 510 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
I. B. Hirsch, B. W. Bode, S. Garg, W. S. Lane, A. Sussman, P. Hu, O. M. Santiago, J. W. Kolaczynski, and for the Insulin Aspart CSII/MDI Comparison Study G
Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII
Diabetes Care, March 1, 2005; 28(3): 533 - 538.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. D Goldman-Levine and K. W Lee
Insulin Detemir--A New Basal Insulin Analog
Ann. Pharmacother., March 1, 2005; 39(3): 502 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. U. Janka, G. Plewe, M. C. Riddle, C. Kliebe-Frisch, M. A. Schweitzer, and H. Yki-Jarvinen
Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes
Diabetes Care, February 1, 2005; 28(2): 254 - 259.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. B. Hirsch
Insulin Analogues
N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Y. C. Kudva, A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza, and W. L. Isley
Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes
Diabetes Care, January 1, 2005; 28(1): 10 - 14.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Duttaroy, P. Kanakaraj, B. L. Osborn, H. Schneider, O. K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, et al.
Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology
Diabetes, January 1, 2005; 54(1): 251 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
W. Kaplan, L. M. Rodriguez, O. E. Smith, M. W. Haymond, and R. A. Heptulla
Effects of Mixing Glargine and Short-Acting Insulin Analogs on Glucose Control
Diabetes Care, November 1, 2004; 27(11): 2739 - 2740.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
E. A. Doyle, S. A. Weinzimer, A. T. Steffen, J. A. H. Ahern, M. Vincent, and W. V. Tamborlane
A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine
Diabetes Care, July 1, 2004; 27(7): 1554 - 1558.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
N. Weintrob, A. Schechter, H. Benzaquen, S. Shalitin, P. Lilos, A. Galatzer, and M. Phillip
Glycemic Patterns Detected by Continuous Subcutaneous Glucose Sensing in Children and Adolescents With Type 1 Diabetes Mellitus Treated by Multiple Daily Injections vs Continuous Subcutaneous Insulin Infusion
Arch Pediatr Adolesc Med, July 1, 2004; 158(7): 677 - 684.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Heise, L. Nosek, B. B. Ronn, L. Endahl, L. Heinemann, C. Kapitza, and E. Draeger
Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes
Diabetes, June 1, 2004; 53(6): 1614 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Riddle, J. Rosenstock, and J. Gerich
The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care, November 1, 2003; 26(11): 3080 - 3086.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Danne, K. Lupke, K. Walte, W. von Schuetz, and M.-A. Gall
Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes
Diabetes Care, November 1, 2003; 26(11): 3087 - 3092.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. D. Phillips, L. A. Aurand, M. M. Bedwell, and J. R. Levy
A Novel Approach to Preventing Diabetic Ketoacidosis in a Patient Treated With an Insulin Pump
Diabetes Care, October 1, 2003; 26(10): 2960 - 2961.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. C. Mellinger
Preparing Students With Diabetes for Life at College
Diabetes Care, September 1, 2003; 26(9): 2675 - 2678.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Hamann, S. Matthaei, C. Rosak, and L. Silvestre
A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes
Diabetes Care, June 1, 2003; 26(6): 1738 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
A. D. Morris
Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes
The Diabetes Educator, May 1, 2003; 29(3): 440 - 453.
[PDF]

Home page
 Diabetes CareHome page
P. Rossetti, S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti, and G. B. Bolli
Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime
Diabetes Care, May 1, 2003; 26(5): 1490 - 1496.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. B. King and D. Armstrong
A Comparison of Basal Insulin Delivery: Continuous subcutaneous insulin infusion versus glargine
Diabetes Care, April 1, 2003; 26(4): 1322 - 1322.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Vague, J.-L. Selam, S. Skeie, I. De Leeuw, J. W.F. Elte, H. Haahr, A. Kristensen, and E. Draeger
Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart
Diabetes Care, March 1, 2003; 26(3): 590 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. S. Schade and V. Valentine
Response to Cersosimo
Diabetes Care, March 1, 2003; 26(3): 967 - 968.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Kalergis, A. Schiffrin, R. Gougeon, P. J.H. Jones, and J.-F. Yale
Impact of Bedtime Snack Composition on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Insulin Management Using Lispro Insulin Before Meals: A randomized, placebo-controlled, crossover trial
Diabetes Care, January 1, 2003; 26(1): 9 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson
Clarifying the Role of Insulin in Type 2 Diabetes Management
Clin. Diabetes, January 1, 2003; 21(1): 14 - 21.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
N. Younis, H. Soran, and D. Bowen-Jones
Insulin glargine: a new basal insulin analogue
QJM, November 1, 2002; 95(11): 757 - 761.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. H. DeVries, F. J. Snoek, P. J. Kostense, N. Masurel, and R. J. Heine
A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control
Diabetes Care, November 1, 2002; 25(11): 2074 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. S. Schade and V. Valentine
To Pump or Not to Pump
Diabetes Care, November 1, 2002; 25(11): 2100 - 2102.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Putz and U. M. Kabadi
Insulin Glargine in Continuous Enteric Tube Feeding
Diabetes Care, October 1, 2002; 25(10): 1889 - 1890.
[Full Text]

Home page
 Diabetes CareHome page
S. Mudaliar, P. Mohideen, R. Deutsch, T. P. Ciaraldi, D. Armstrong, B. Kim, X. Sha, and R. R. Henry
Intravenous Glargine and Regular Insulin Have Similar Effects on Endogenous Glucose Output and Peripheral Activation/Deactivation Kinetic Profiles
Diabetes Care, September 1, 2002; 25(9): 1597 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002
Diabetes Care, September 1, 2002; 25(9): 1644 - 1649.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Lindstrom, C. A. Hedman, and H. J. Arnqvist
Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs
Diabetes Care, June 1, 2002; 25(6): 1049 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
C. G. Fanelli, S. Pampanelli, F. Porcellati, P. Rossetti, P. Brunetti, and G. B. Bolli
Administration of Neutral Protamine Hagedorn Insulin at Bedtime versus with Dinner in Type 1 Diabetes Mellitus To Avoid Nocturnal Hypoglycemia and Improve Control: A Randomized, Controlled Trial
Ann Intern Med, April 2, 2002; 136(7): 504 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. A. Adlersberg, S. Fernando, G. R. Spollett, and S. E. Inzucchi
Glargine and Lispro: Two cases of mistaken identity
Diabetes Care, February 1, 2002; 25(2): 404 - 405.
[Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
C.-S. Yuan, G. Wei, J. F. Foss, M. O'Connor, T. Karrison, and J. Osinski
Effects of Subcutaneous Methylnaltrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 118 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
R. A. Guthrie, D. Hinnen, and B. P. Childs
Glargine: A New Basal Insulin, A New Opportunity
Diabetes Spectr, August 1, 2001; 14(3): 120 - 122.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.